Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viremia Clear all
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 4 Interventional Results available

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

NCT00662545
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Entecavir with continued standard of care antiretroviral therapy, continued standard of care with tenofovir in addition to emtricitabine or lamivudine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

NCT01933594
View directory record Official record
Conditions
HIV Infections
Interventions
Romidepsin, Placebo for Romidepsin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 3 Interventional

Intermittent vs. Continuous HAART to Treat Chronic HIV Infection

NCT00025909
View directory record Official record
Conditions
HIV Infection
Interventions
Leukapheresis
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT01646645
View directory record Official record
Conditions
Cytomegalovirus
Interventions
CMV-pp65 CTLs
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 10, 2026, 3:30 AM EDT
Not listed Not applicable Interventional

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

NCT00102934
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide-intensified HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

NCT01498484
View directory record Official record
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Interventions
EBV-specific T cells (EBV-CTLs)
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
Not listed
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 10, 2026, 3:30 AM EDT
Completed No phase listed Observational

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

NCT00050063
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 3:30 AM EDT
Terminated Phase 2 Interventional Results available

Emtricitabine/Tenofovir Alafenamide as Salvage ART

NCT02556333
View directory record Official record
Conditions
HIV
Interventions
FTC/TAF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 1 Interventional Results available

Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine

NCT05691530
View directory record Official record
Conditions
Response To Dengue Exposure
Interventions
rDEN3Δ30/31-7164
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 59 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 10, 2026, 3:30 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

NCT03283826
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
ATA188, Placebo
Biological · Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 2 Interventional

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

NCT00000790
View directory record Official record
Conditions
HIV Infections, Stomatitis, Aphthous
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 10, 2026, 3:30 AM EDT
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 10, 2026, 3:30 AM EDT
Completed No phase listed Observational Results available

BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients

NCT01782209
View directory record Official record
Conditions
BK Virus (BKV) Viremia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 4 Interventional Results available

Raltegravir Intensification in HIV-infected Patients

NCT00631449
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797
View directory record Official record
Conditions
CMV Infection, Persistent CMV Viremia
Interventions
CMVpp65 Specific T-cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (MK-0518), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

NCT04769167
View directory record Official record
Conditions
Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
Interventions
Stool and Blood Specimen Collection, Follow-up Medical Record Review
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

NCT00618371
View directory record Official record
Conditions
HIV Infection
Interventions
Raltegravir (MK-0518)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Phase 1 Interventional

IVIg to Treat BK Viremia in Kidney Transplant Recipients

NCT02659891
View directory record Official record
Conditions
Kidney Transplantation, BK Virus, Isoantibodies
Interventions
IVIg, Placebo
Biological · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 10, 2026, 3:30 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Using Telehealth to Address Alcohol Misuse in HIV Care

NCT04546971
View directory record Official record
Conditions
Alcohol Drinking, HIV Viremia
Interventions
Brief Intervention, Telehealth Counseling, Text messaging
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Sep 10, 2026, 3:30 AM EDT
Not yet recruiting Phase 4 Interventional

Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

NCT07571135
View directory record Official record
Conditions
CMV Infection, CMV, CMV Viremia, CMV Disease
Interventions
Letermovir, Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
Elisabeth Kincaide
Government
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 10, 2026, 3:30 AM EDT
Completed Not applicable Interventional Results available

Using mTOR Inhibitors in the Prevention of BK Nephropathy

NCT01649609
View directory record Official record
Conditions
BK Viremia, BK Nephropathy
Interventions
Tacrolimus, Mycophenolate acid, Sirolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 10, 2026, 3:30 AM EDT